Lenalidomide Combined With Rituximab as Front-line Therapy for DLBCL Patients Aged Over 80 Years
Status:
Recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
About 40% of Diffuse large B cell lymphoma relapse or is refractory, age is a prognostic
factor of DLBCL, as elderly patients are not capable to received standard treatment, the
prognosis of elderly patients is poor especially those aged over 80 years. In this study,we
aimed to investigate the safety and efficacy of the combination of lenalidomide and rituximab
in elderly patients aged ≥ 80 years with untreated DLBCL.
Phase:
Phase 2
Details
Lead Sponsor:
Guangdong Provincial People's Hospital
Collaborators:
Foshan First People's Hospital Guangzhou First People's Hospital Huizhou Municipal Central Hospital Shantou Central Hospital